Gleamer's 'OncoView' project will be partially funded by the French government

Medtech startup Gleamer, a leading provider of AI systems for medical imaging, plans to invest €18 million over five years in a new project to support radiologists in assessing and interpreting oncology CT scans. The project will join Gleamer's portfolio of radiology solutions including BoneView (bone trauma detection), ChestView (thoracic pathology detection), BoneMetrics (MSK measurement automation), and BoneAge (bone maturity assessment). Gleamer also works on BreastView, a module for early breast cancer detection in mammogram imaging.

The project, known as "OncoView", will be partially funded by the French government, as it has been chosen as a France 2030 laureate. France 2030 is a government-launched project that aims to invest €54 million across five years to foster competition and innovation in key areas such as healthcare, agriculture, and energy. Out of the program's total funding, €4.5 million will be provided by the France 2030 program.

OncoView is expected to improve diagnostic accuracy by supporting the detection of cancerous lesions likely to remain unnoticed and "providing reliable and consistent evaluations of treatment outcomes." The intention is that these tools for enhanced diagnostics allow patients to have personalized care pathways that are better suited to their needs. The first types of cancerous lesions targeted by OncoView for detection, measurement, and monitoring will be bone and lung lesions, as they are known to be two common metastatic sites.

Independently of the France 2030 financing, Gleamer has raised nearly €36 million from an impressive investor roster, including Supernova Invest, Heal Capital, xAnge, Elaia, and Bpi France.